Nelson Advisors thought leadership has been referenced in the Forbes article '5 High-Growth Business Models Set To Thrive In The Coming Decade' outlining five business models that are primed for success in the coming years.

The major stories in the world of European MedTech this week are dominated by regulatory activity under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), a significant European Commission "Call for Evidence" for future reforms, and fresh funding for companies focused on connected and remote monitoring devices.

The UK HealthTech mergers and acquisitions (M&A) market in 2025 is characterised by a "cautious yet discernible rebound". While global digital health funding has seen a decline, the European market, particularly within the UK, has demonstrated remarkable resilience, defying global trends with a significant surge in deal activity. This momentum is not uniform, however; it is marked by a profound bifurcation that separates the market into two distinct categories.

The IPO landscape for HealthTech startups in 2025 is likely to be dynamic, influenced by various factors such as market conditions, company performance and regulatory changes. While it's challenging to predict with certainty which specific companies will go public, the following six HealthTech startups have the potential to be among the IPO candidates: Omada Health, Hinge Health, Sword Health, Doctolib, Aledade, Quantum Health